Breaking News Instant updates and real-time market news.

QURE

uniQure

$53.57 /

-0.96 (-1.76%)

07:55
02/27/20
02/27
07:55
02/27/20
07:55

uniQure presents new preclinical data on AMT-130

uniQure announced the presentation of multiple new preclinical data on AMT-130, its investigational AAV gene therapy for the treatment of Huntington's disease, at the 15th Annual CHDI Huntington's disease Therapeutics Conference in Palm Springs, California. Four scientific abstracts submitted by uniQure researchers were accepted for presentation at the conference, of which one is an oral presentation to be featured. Important findings across several preclinical studies presented at the conference include the following: Translatable Biomarkers in Gene Therapy for Huntington Disease: Learnings from Pre-clinical Studies In identifying translatable biomarkers for gene therapy studies in Huntington's disease, transgenic Huntington's disease minipigs were used to assess the biodistribution and target engagement in a larger brain. The minipig model is the largest diseased animal model available, generally weighing up to 300 pounds. AMT-130 was administered by MRI-guided convention-enhanced delivery at a single dose, bilaterally in the caudate and putamen. Vector DNA distribution and transgene expression in minipig brains demonstrated extensive brain coverage comparable at the two interim sacrifice timepoints of 6- and 12-months post administration, leading to significant lowering of mutant huntingtin protein in the brain. At 12 months, the most pronounced mHTT protein lowering was observed in the putamen, caudate and amygdala, followed by thalamus and cerebral cortex. The ongoing study that now includes up to two years of follow-up, demonstrated stable mHTT protein lowering of up to 30 percent in the cerebrospinal fluid of minipigs after a single administration of AMT-130. Secreted Therapeutics: Monitoring Durability of microRNA-based Gene Therapies in Huntington's disease Neurons derived from the induced pluripotent stem cells of Huntington's disease patients were used to study the presence of extracellular therapeutic microRNA targeting human huntingtin after transduction with AMT-130. Extracellular vesicles were identified as carriers of RNA species, including microRNAs, and are therefore potential biomarkers for diagnosis and pharmacokinetics. Results from this new study demonstrated that therapeutic miHTT molecules are secreted in a dose-dependent manner from AMT-130-treated neuronal cells, providing the potential of a promising translational marker to monitor long-term expression of AMT-130 gene therapy in the brain. To support these results, non-human primates received a single administration of AMT-130 resulting in widespread distribution of therapeutic miHTT molecules in both the striatum and cortex, as well as the presence of therapeutic miHTT molecules in the CSF up to 6 months after intrastriatal injection of AMT-130. Lowering the Pathogenic Exon 1 HTT Fragment by AAV5-miHTT Gene Therapy In a study using the Q175FDN mouse model, the target engagement of aberrantly spliced exon 1 HTT transcript was investigated. These new preclinical data demonstrated that the mice treated with AMT-130 experienced a dose-dependent lowering of exon 1 HTT mRNA in both the striatum and cortex, as well as the full-length HTT mRNA. The lowering was shown to be well correlated with the detected levels of vector DNA and mature miHTT molecules in the mice treated with AMT-130. Exploring the Effects of Intrastriatal AAV5-miHTT Lowering Therapy on Neuronal Function, MRS Signal and Mutant Huntingtin Levels in the Q175FDN Mouse Model of Huntington's disease Magnetic resonance spectroscopy data in the Q175FDN mouse model of Huntington's disease demonstrate that levels of N-acetyl aspartate, a neuronal integrity marker, were restored in mice treated with the high dose of AMT-130, supporting the use of imaging biomarkers in gene therapy studies for Huntington's disease. Importantly, effects of mHTT silencing in the Q175FDN model on MRS were complemented by additional data on striatal gene expression profiles, demonstrating a trend towards normalization with AMT-130 treatment. These new data build on earlier MRS and MRI data suggesting improvement in brain cell function, a reversal in Huntington's disease neuropathology and a partial reversal of volume loss in the hippocampus, a key brain region involved in memory.

QURE uniQure
$53.57 /

-0.96 (-1.76%)

01/23/20 Cantor Fitzgerald
Cantor sees further upside in uniQure, calls 'highly attractive' buyout candiate
12/10/19 Mizuho
uniQure price target raised to $90 from $67 at Mizuho
12/09/19 Piper Sandler
Piper says uniQure solidified 'front runner' position in Hemophilia B at ASH
12/09/19 H.C. Wainwright
uniQure has 'best in class' hemophilia B profile, says H.C. Wainwright

TODAY'S FREE FLY STORIES

Upgrade
Centerra Gold upgraded to Buy from Hold at TD Securities » 07:50
04/01/20
04/01
07:50
04/01/20
07:50
CAGDF

Centerra Gold

$0.00 /

+ (+0.00%)

TD Securities analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Boyd Gaming upgraded to Positive from Neutral at Susquehanna » 07:49
04/01/20
04/01
07:49
04/01/20
07:49
BYD

Boyd Gaming

$14.38 /

-0.77 (-5.08%)

Susquehanna analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Crombie REIT downgraded to Hold from Buy at TD Securities » 07:49
04/01/20
04/01
07:49
04/01/20
07:49
CROMF

Crombie REIT

$0.00 /

+ (+0.00%)

TD Securities analyst Sam…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Initiation
Zynex initiated with an Outperform at Northland » 07:47
04/01/20
04/01
07:47
04/01/20
07:47
ZYXI

Zynex

$11.05 /

+0.25 (+2.31%)

Northland analyst James…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Expedia downgraded to Hold from Buy at Argus » 07:47
04/01/20
04/01
07:47
04/01/20
07:47
EXPE

Expedia

$56.39 /

-0.07 (-0.12%)

Argus analyst John…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Target Hospitality downgraded to Market Perform from Outperform at Northland » 07:47
04/01/20
04/01
07:47
04/01/20
07:47
TH

Target Hospitality

$1.98 /

+0.13 (+7.03%)

Northland analyst Jeff…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Ritchie Bros. upgraded to Hold from Reduce at TD Securities » 07:45
04/01/20
04/01
07:45
04/01/20
07:45
RBA

Ritchie Bros.

$34.12 /

+0.93 (+2.80%)

TD Securities analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Chubb price target lowered to $150 from $182 at Wells Fargo » 07:45
04/01/20
04/01
07:45
04/01/20
07:45
CB

Chubb

$111.26 /

-2.84 (-2.49%)

Wells Fargo analyst Elyse…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Palo Alto seeing firewall pickup due to 'WFH' trend, says Rosenblatt » 07:45
04/01/20
04/01
07:45
04/01/20
07:45
PANW

Palo Alto Networks

$163.87 /

-3.21 (-1.92%)

After Palo Alto Networks…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Barrick Gold upgraded to Action List Buy from Hold at TD Securities » 07:45
04/01/20
04/01
07:45
04/01/20
07:45
GOLD

Barrick Gold

$18.32 /

-0.96 (-4.98%)

TD Securities analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Brighthouse Financial price target lowered to $29 from $37 at Wells Fargo » 07:44
04/01/20
04/01
07:44
04/01/20
07:44
BHF

Brighthouse Financial

$24.16 /

-1.36 (-5.33%)

Wells Fargo analyst Elyse…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Axis Capital price target lowered to $43 from $60 at Wells Fargo » 07:43
04/01/20
04/01
07:43
04/01/20
07:43
AXS

Axis Capital

$38.68 /

+0.12 (+0.31%)

Wells Fargo analyst Elyse…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Astec upgraded to Outperform at Baird » 07:42
04/01/20
04/01
07:42
04/01/20
07:42
ASTE

Astec

$34.84 /

+2.38 (+7.33%)

Baird analyst Mircea…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Arthur J. Gallagher price target lowered to $112 from $121 at Wells Fargo » 07:41
04/01/20
04/01
07:41
04/01/20
07:41
AJG

Arthur J. Gallagher

/

+

Wells Fargo analyst Elyse…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Zillow price target lowered to $44 from $70 at Citi » 07:41
04/01/20
04/01
07:41
04/01/20
07:41
ZG

Zillow

$34.05 /

-0.67 (-1.93%)

Citi analyst Nicholas…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Arch Capital price target lowered to $40 from $52 at Wells Fargo » 07:41
04/01/20
04/01
07:41
04/01/20
07:41
ACGL

Arch Capital

$28.44 /

-2.11 (-6.91%)

Wells Fargo analyst Elyse…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Bruker double-downgraded to Hold at Needham after adverse internal inquiry » 07:40
04/01/20
04/01
07:40
04/01/20
07:40
BRKR

Bruker

$35.88 /

-2.67 (-6.93%)

As previously reported,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Aon plc price target lowered to $232 from $265 at Wells Fargo » 07:40
04/01/20
04/01
07:40
04/01/20
07:40
AON

Aon plc

$165.10 /

-5.58 (-3.27%)

Wells Fargo analyst Elyse…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Disney price target lowered to $130 from $170 at Morgan Stanley » 07:39
04/01/20
04/01
07:39
04/01/20
07:39
DIS

Disney

$96.54 /

-3.3 (-3.31%)

Morgan Stanley analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Trade Desk price target lowered to $240 from $280 at Citi » 07:39
04/01/20
04/01
07:39
04/01/20
07:39
TTD

Trade Desk

$193.03 /

-4.5 (-2.28%)

Citi analyst Mark May…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
AIG price target lowered to $38 from $66 at Wells Fargo » 07:38
04/01/20
04/01
07:38
04/01/20
07:38
AIG

AIG

$24.23 /

-1.39 (-5.43%)

Wells Fargo analyst Elyse…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
SuperCom's PureSecurity security suite adopted by Canadian agency » 07:38
04/01/20
04/01
07:38
04/01/20
07:38
SPCB

SuperCom

$0.92 /

-0.096 (-9.41%)

SuperCom's…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Hawaiian Holdings upgraded to Hold from Sell at Stifel » 07:35
04/01/20
04/01
07:35
04/01/20
07:35
HA

Hawaiian Holdings

$10.41 /

-0.19 (-1.79%)

Stifel analyst Joseph…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Proximus upgraded to Hold from Sell at Deutsche Bank » 07:35
04/01/20
04/01
07:35
04/01/20
07:35
BGAOF

Proximus

$0.00 /

+ (+0.00%)

Deutsche Bank analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Options
Unusual call flow in option market yesterday » 07:35
04/01/20
04/01
07:35
04/01/20
07:35
NET

Cloudflare

$23.50 /

-0.39 (-1.63%)

Notable call activity was…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.